ALGRX 4975
Phase 2Small molecule
ALGRX 4975 is one of 10 small molecule programs targeting Hernia. It is currently in Phase 2.
2
Indications
8
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
15 competitors in Neuroma
#DrugCompanyPhaseTrials
1IC-Green
CCHX Technologies Inc.
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 2
Xylocaine
MMEDRx USA, Inc.
Phase 1
Medrol
PfizerPreclinical
Xylocaine
AstraZenecaPhase 1
CNTX-4975
CCentrexion Therapeutics
Phase 2
ALGRX 4975
AAlgoRx Pharmaceuticals
Phase 2
Onabotulinum Toxin Type a
SSouthern Illinois University
Phase 2
Resiniferatoxin
SSorrento Therapeutics, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Efficacy and Safety3 trials
Hernia1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ALGRX 4975. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAlgoRx Pharmaceuticals